Online Only Articles

Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial

Biology Platform, Sunnybrook Research Institute, Toronto;Dept. of Medical Biophysics, University of Toronto, Toronto;Sunnybrook Odette Cancer Center, Toronto;Dept. of Medicine, University of Toronto, Canada;Dept. of Immunology, University of Toronto, Canada
Biology Platform, Sunnybrook Research Institute, Toronto
Biology Platform, Sunnybrook Research Institute, Toronto
Biology Platform, Sunnybrook Research Institute, Toronto
Toronto East-General Hospital, Canada
Sunnybrook Odette Cancer Center, Toronto
Biology Platform, Sunnybrook Research Institute, Toronto
Vol. 101 No. 5 (2016): May, 2016 https://doi.org/10.3324/haematol.2015.135418